Brazilian researchers have discovered why the guardian of the genome, p53, is uniquely prone to structural failure compared to its more robust relatives. The study identifies molecular gaps and structural frustration that trigger p53 cancer-linked aggregation, revealing how the protein sequence balances flexibility with vulnerability. These findings, stemming from over twenty years of research, provide a new roadmap for next-generation cancer therapies focused on stabilizing this critical protein.